IntelliGenes, a first-of-its-kind software created at Rutgers Health, combines artificial intelligence (AI) and machine-learning approaches to measure the significance of specific genomic biomarkers to help predict diseases in individuals, according to its developers. A study published in Bioinformatics explains how IntelliGenes can be utilized by a wide range of users to analyze multigenomic and clinical data.

Zeeshan Ahmed, lead author of the study and a faculty member at Rutgers Institute for Health, Health Care Policy and Aging Research (IFH), said there currently are no AI or machine-learning tools available to investigate and interpret the complete human genome, especially for nonexperts. Ahmed and members of his Rutgers lab designed IntelliGenes so anyone can use the platform, including students or those without strong knowledge of bioinformatics techniques or access to high-performing computers. To read the full story.